The use of highmolecular-weight hyaluronic acid in the treatment of osteoarthritis
https://doi.org/10.14412/1996-7012-2017-1-62-65
Abstract
Osteoarthritis (OA) is one of the most common diseases of the musculoskeletal system, affecting mainly people of old age. The management of OA requires combined therapy using pharmaceutical and nonpharmacological modalities, including hyaluronic acid (HA). Hylans are highmolecular-weight (HMW) HA derivatives. The use of hylans results in reducing pain and stiffness and in improving functional activity. Their efficacy is comparable with that of lowmolecular-weight HA. Intraarticular injection of HMW HA derivatives is safe and effective for treating OA.
About the Author
S. G. Anikin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Lane NE, Brandt K, Hawker G, et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage. 2011 May;19(5):478-82. doi: 10.1016/j.joca.2010.09.013. Epub 2011 Mar 23.
2. Насонова ВА. Проблема остеоартроза в начале ХХI века. Consilium Medicum. 2000;2(6):61-4. [Nasonova VA. The problem of osteoarthritis in the early twenty-first century. Consilium Medicum. 2000;2(6):61–4. (In Russ.)]
3. Галушко ЕА. Медико-социальная значимость ревматических заболеваний. Автореф. дисс. докт. мед. наук. Москва; 2011. 47 с. [Galushko EA. Medical and social importance of rheumatic diseases. Autoref. diss. doct. med. sci. Moscow; 2011. 47 p.]
4. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis- From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45 (4 Suppl):S3-11. doi: 10.1016/j.semarthrit.2015. 11.010. Epub 2015 Dec 2.
5. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005321.
6. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.
7. Espallargues M, Pons JM. Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis: a systematic review. Int J Technol Assess Health Care. 2003 Winter;19(1):41-56.
8. Pai SK, Allgar V, Giannoudis PV. Are intraarticular injections of Hylan G-F 20 efficacious in painful osteoarthritis of the knee? A systematic review & meta-analysis. Int J Clin Pract. 2014 Aug;68(8):1041-7. doi: 10.1111/ijcp.12430. Epub 2014 May 5.
9. Migliore A, Bizzi E, Herrero-Beaumont J, et al. The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap! Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1124-9.
10. Petrella RJ, Wakeford C. Pain relief and improved physical function in knee osteoarthritis patients receiving ongoing hylan G-F 20, a highmolecular- weight hyaluronan, versus other treatment options: data from a large real-world longitudinal cohort in Canada. Drug Des Devel Ther. 2015 Oct 15;9:5633-40. doi: 10.2147/DDDT.S88473. eCollection 2015.
11. Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015 Jan 6;162(1):46-54. doi: 10.7326/M14-1231.
12. Waddell D. Viscosupplementation: Evidence for a Mechanism of Action. Paper Presented at: Annual Meeting of the Academy of Orthopedic Surgeons; March 10-14. San Francisco; 2004.
13. Waddell DD, Marino AA. Chronic knee effusions in patients with advanced osteoarthritis: implications for functional outcome of viscosupplementation. J Knee Surg. 2007 Jul;20(3):181-4.
14. Waddell BS, Waddell WH, Waddell DD. Comparison of Efficacy and Tolerability of Hylan G-F 20 in Patients with and without Effusions at the Time of Initial Injection. J Knee Surg. 2015 Jun;28(3):213-22. doi: 10.1055/s-0034-1376328. Epub 2014 May 7.
15. Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum. 2007 Dec 15;57(8):1410-8.
16. Zhao H, Liu H, Liang X, et al. Hylan G-F 20 Versus Low Molecular Weight Hyaluronic Acids for Knee Osteoarthritis: A Meta-Analysis. BioDrugs. 2016 Oct;30(5):387-96.
17. Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996 Sep;23(9):1579-85.
18. Conrozier T, Chevalier X. Long-term experience with hylan GF-20 in the treatment of knee osteoarthritis. Expert Opin Pharmacother. 2008 Jul;9(10):1797-804. doi: 10.1517/14656566.9.10.1797.
Review
For citations:
Anikin SG. The use of highmolecular-weight hyaluronic acid in the treatment of osteoarthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2017;11(1):62-65. (In Russ.) https://doi.org/10.14412/1996-7012-2017-1-62-65
Views:
860
Email this article 